The Prognostic Impact of P32 Deletion in Newly Diagnosed Multiple Myeloma

Deletion 17P is believed to be the most unfavorable one and affects approximately 8% of patients with newly diagnosed multiple myeloma. Deletion 1P32 was defined by the deletion of at least FAF1 or CDKN2C genes. The purpose of the current study was to assess the prognostic impact of one P32 deletion in a large cohort of newly diagnosedMultiple Myeloma patients, irrespective of the treatment received.